Molecular Templates Inc
(NAS:MTEM)
$
1.4378
-0.0772 (-5.1%)
Market Cap: 9.47 Mil
Enterprise Value: 8.71 Mil
PE Ratio: 0
PB Ratio: 1.33
GF Score: 54/100 - Molecular Templates Inc at Oppenheimer Healthcare Conference (Virtual) TranscriptMar 15, 2023
- G1 Therapeutics Inc, Molecular Templates Inc, Olema Pharmaceuticals Inc and Puma Biotechnology Inc at Cowen Health Care Conference- Panel TranscriptMar 07, 2023
- Molecular Templates Inc at Piper Sandler Healthcare Conference TranscriptDec 01, 2022
- Molecular Templates Inc at Evercore ISI HealthCONx Conference (Virtual) TranscriptNov 30, 2022
- Molecular Templates Inc To Present Interim Data and Host R&D Day at The Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting TranscriptNov 11, 2022
- Molecular Templates Inc To Discuss Unique Approach To Immuno-Oncology For Solid Tumors Call TranscriptApr 13, 2022
- Molecular Templates Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) TranscriptSep 20, 2021
- Molecular Templates Inc at Barclays Global Healthcare Conference (Virtual) TranscriptMar 10, 2021
- Molecular Templates Inc To Discuss The Use of Egineer Toxin Bodies (EBTs) TranscriptSep 29, 2020
- Molecular Templates Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 17, 2020
- Molecular Templates Inc at UBS Global Healthcare Conference (Virtual) TranscriptMay 18, 2020
- Molecular Templates Inc R&D Day TranscriptNov 15, 2019
- Molecular Templates Inc at UBS Global Healthcare Conference TranscriptMay 20, 2019
Molecular Templates Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
Nov 30, 2022 / 02:15PM GMT
Release Date Price:
$7.95
(+2.89%)
Jonathan Miller
Evercore ISI - Analyst
Good morning, everybody, and welcome to our chat with Eric from Molecular Templates. Thanks so much for joining us again for another year of this conference, Eric. I'd love to start with -- well, let's start with a little intro from you. I think you've got multiple programs in the clinic right now, a lot of irons in the fire and some interesting initial clinical activity. So how do you view Molecular Templates going forward into the next year?
Questions & Answers
Eric Poma
Molecular Templates, Inc. - CEO & Chief Scientific Officer
Yeah. First, thanks again for the invite. This is always the best conference of the year, so my appreciations.
Jonathan Miller
Evercore ISI - Analyst
Say that to all the sell-siders, I'm sure.
Eric Poma
Molecular Templates, Inc. - CEO & Chief Scientific Officer
Sure. Look, I think it's been a good year for us. I think we have three drugs in the clinic that are either through Phase 1
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)